Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Bioverativ Usa Inc. is currently managing 3 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 3 distinct examiners and 3 distinct art units. This distribution indicates that the company's patent applications are undergoing review in several different technical divisions at the USPTO, reflecting a diverse technical scope that spans multiple biotechnological specializations.
XIAO, YAN is identified as the busiest examiner, holding 1 pending office action. Since there are 3 pending office actions in total, each of the 3 distinct examiners is responsible for one action. This means the workload is evenly spread, and no single examiner has a dominant role in the portfolio's current prosecution. The involvement of 3 distinct art units suggests that the company's innovations cover a variety of sub-fields, each requiring a tailored response.
Practitioners must coordinate responses to 3 pending office actions across three different administrative units, addressing the specific concerns of three separate examiners. With 1 pending office action assigned to each examiner, the company faces three separate technical dialogues. This decentralized structure, involving 3 distinct examiners and 3 distinct art units, requires careful management to ensure that the prosecution of each application remains on track without a central point of contact.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 2 (67%) |
| No statute on record | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| XIAO, YAN | 1 | 67.3% | +52.7% |
| KIM, YUNSOO | 1 | 65.9% | +34.3% |
| HOWARD, ZACHARY C | 1 | 64.0% | +37.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18477981 | REDUCING SURGERY-ASSOCIATED HEMOLYSIS IN COLD AGGLUTININ DISEASE PATIENTS | XIAO, YAN | — |
| 18334567 | ANTI-COMPLEMENT C1S ANTIBODY FORMULATION | KIM, YUNSOO | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17818885 | HUMANIZED ANTI-C1S ANTIBODIES AND METHODS OF USE THEREOF | HOWARD, ZACHARY C | 36d overdue |
| 18477981 | REDUCING SURGERY-ASSOCIATED HEMOLYSIS IN COLD AGGLUTININ DISEASE PATIENTS | XIAO, YAN | — |
| 18334567 | ANTI-COMPLEMENT C1S ANTIBODY FORMULATION | KIM, YUNSOO | — |
| Art Unit | Apps |
|---|---|
| 1642 | 1 |
| 1644 | 1 |
| 1674 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18477981 | REDUCING SURGERY-ASSOCIATED HEMOLYSIS IN COLD AGGLUTININ DISEASE PATIENTS | XIAO, YAN | 1642 | §102§103 | Non-Final OA | — | Pending | Sep 29, 2023 |
| 18334567 | ANTI-COMPLEMENT C1S ANTIBODY FORMULATION | KIM, YUNSOO | 1644 | §103§112 | Non-Final OA | — | Pending | Jun 14, 2023 |
| 17818885 | HUMANIZED ANTI-C1S ANTIBODIES AND METHODS OF USE THEREOF | HOWARD, ZACHARY C | 1674 | Other | Final Rejection | 36d overdue | Pending | Aug 10, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial